Laferon-PharmBiotek® Suppositories – Antiviral Drug Containing Human Recombinant Interferon Alpha-2b

Trade Name: Laferon-PharmBiotek® Suppositories

ATC Code: L03A B05

Dosage Form: Rectal suppositories 250,000 IU, No. 10; 500,000 IU, No. 10

Mechanism of Action:

Laferon-PharmBiotek® Suppositories exhibit a broad spectrum of biological activity. The primary effects include pronounced antiviral and immunostimulatory action, as well as activation of antitumor defense.

Interferons regulate interactions between components of cellular and humoral immunity, modulate the production of inflammatory mediators, and exert direct antiviral effects by inhibiting viral attachment, replication, transcription, and other processes. Additionally, interferons have high anti-chlamydial activity.

The use of Laferon-PharmBiotek® Suppositories as part of combination therapy for chronic infectious-inflammatory diseases enhances the efficacy of antibacterial and other drugs used in treatment, reduces their systemic toxic effects, and shortens the duration of treatment.

Indications for Use:

Laferon-PharmBiotek® rectal suppositories are used in children and adults as monotherapy or as part of combination therapy for various viral and viral-bacterial infections. The drug is indicated for the treatment of:

• Influenza and acute respiratory viral infections (ARVI);
• Viral-bacterial infections of the respiratory tract;
• Pediatric viral infectious diseases (mumps, measles, rubella, chickenpox, mononucleosis);
• Rotavirus infection;
• Chronic viral hepatitis B in children;
• Congenital infections (TORCH infections), pneumonia, sepsis, meningitis in children;
• Cervical dysplasia associated with human papillomavirus (HPV);
• Chronic infectious-inflammatory diseases of the urogenital tract.

The drug is also used for the rehabilitation of children who frequently suffer from respiratory infections.